Fig. 2

Network diagram of the primary outcomes evaluated at 6-month follow-up in included randomized clinical trials. The size of nodes and lines is proportional to the number of participants allocated to each intervention and comparison. The colors of the nodes and lines correspond to the risk of bias of the included studies (green—Low risk; yellow—some concerns; and red—high risk). a - ACR 50; b - PsARC; c - Serious adverse events. Abbreviations: ADA adalimumab; CER certolizumab pegol; ETA etanercept; GOL golimumab; IFN infliximab; SEC secukinumab; PBO placebo; TOF tofacitinib